OpenClinica enters strategic alliance with Athena Healthcare to provide clinical trials software to the Chinese market

OpenClinica enters strategic alliance with Athena Healthcare to provide clinical trials software to the Chinese market

OpenClinica, has entered into a strategic alliance with Athena Healthcare Consultancy to bring the OpenClinica clinical trials software to the Chinese market.


Athena Healthcare Consultancy
Quote startFor the past 6 years OpenClinica has been used in FDA regulated clinical trials. We are excited to bring this world-class technology to China, which is increasing its standards for clinical research.Quote end

Waltham, MA (PRWEB) August 25, 2011

OpenClinica, LLC has entered into a strategic alliance with Athena Healthcare Consultancy to bring the OpenClinica clinical trials software to the Chinese market. Headquartered in Shanghai, Athena will be the exclusive distributor of the OpenClinica Enterprise edition and provide localized support and services for Contract Research Organizations (CRO), pharmaceutical companies, and scientific institutes operating in China.

As the world's fastest growing clinical trial software, OpenClinica provides web-based electronic data capture and clinical data management functions that are increasingly critical to conducting efficient clinical trials in today's highly regulated research environments.

Ben Baumann, OpenClinica's Director of Business Development, says "For the past 6 years OpenClinica has been used in FDA regulated clinical trials. We are excited to bring this world-class technology to China, which is increasing its standards for clinical research."

While China has its own rapidly growing biopharmaceuticals industry, global clinical trial sponsors are increasing their amount of research being conducted in China. Improving regulations, a large patient population, and capable and motivated investigators are some of the factors that make China an increasingly appealing place to conduct research.

Athena Healthcare Consultancy General Manager Ivan Tjong-A-Hung, MD says, "This alliance will allow us to better support China's growing pharmaceutical and biotech research industries with a complete, fully localized solution for running clinical trials more productivity and according to global standard good clinical practices."

For more information, see http:// http://www.openclinica.cn.

Contacts:

For OpenClinica
Matt Ellis
matt(at)ellisstrategies(dot)com
617-278-6560

For Athena Healthcare
Ivan Tjong-a-Hung, MD
ivan.tjong-a-hung(at)athena-healthcare(dot)com
+86 21 62470810

About OpenClinica®
OpenClinica enhances the productivity of clinical trials through commercial open source software. Trusted by hundreds of biopharmaceutical companies, contract research organizations, academic, and government organizations worldwide, the OpenClinica software facilitates electronic data capture and data management, increasing the speed of collection and quality of data in clinical trials. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulatory guidelines and is designed as a standards-based, extensible, and modular platform. For more information - including product downloads - visit http://www.openclinica.com or follow @OpenClinica on Twitter.

About Athena Healthcare Consultancy
Since 2005, Athena Healthcare Consultancy has provided clinical research, medical publishing, and pharmaceutical marketing services in China. Athena's experience covers diverse therapeutic areas including cardiovascular, diabetes, neurology, and allergy (END, dermatology), and oncology. The company's clients include international biopharmaceutical companies, academic and government research institutes, and contract research organizations. For more information see http://www.openclinica.cn.

Contact

* Matt Ellis
[email protected]
617-278-6560
Email

 

 

Suggested Articles

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company.

The RV144 HIV vaccine regimen containing clades B and E inserts produced strong immune responses in South Africa, where clade C dominates.